近期论文
查看导师最新文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
1. Yang LL, Li GB, Ma S, Zou C, Zhou S, Sun QZ, Cheng C, Chen X, Wang LJ, Feng S, Li LL, Yang SY*. Structure-Activity Relationship Studies of Pyrazolo[3,4-d]Pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity Against Acute Myeloid Leukemia in Vitro and in Vivo. J Med Chem, 2013, 56(4): 1641-1655. 2. Li GB,Yang LL, Wang WJ, Li LL,Yang SY*. ID-Score: A New Empirical Scoring Function Based on a Comprehensive Set of Descriptors Related to Protein−Ligand Interactions. J Chem Inf Model, 2013, 53(3): 592–600. 3. Cao ZX, Liu JJ, Zheng RL, Yang J, Zhong L, Xu Y, Wang LJ, Zhang CH, Wang BL, Ma S, Wang ZR, Xie HZ, Wei YQ, Yang SY*. SKLB1028, a Novel Oral Multikinase Inhibitor of EGFR, FLT3 and Abl, Displays Exceptional Activity in Models of FLT3-driven AML and Considerable Potency in Models of CML Harboring Abl Mutants. Leukemia, 2012, 26(8): 1892-1895. 4. Yang J, Wang LJ, Liu JJ, Zhong L, Zheng RL, Xu Y, Ji P, Zhang CH, Wang WJ, Lin XD, Li LL, Wei YQ, Yang SY*. Structural Optimization and Structure-Activity Relationships of N-2-(4-(4-Methylpiperazin- 1-yl)phenyl)- N-8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations. J Med Chem, 2012, 55(23): 10685-10699. 5. Li WW, Wang XY, Zheng RL, Yan HX, Cao ZX, Zhong L, Wang ZR, Ji P, Yang LL, Wang LJ, Xu Y, Liu JJ, Yang J, Zhang CH, Ma S, Feng S, Sun QZ, Wei YQ, Yang SY*. Discovery of the Novel Potent and Selective FLT3 Inhibitor 1-{5-[7-(3-Morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl }-3-ptolylurea and Its Anti-Acute Myeloid Leukemia (AML) Activities in Vitro and in Vivo. J Med Chem, 2012, 55(8): 3852-3866. 6. Pan YL, Xu Y, Feng S, Luo SD, Zheng RL, Yang J, Wang LJ, Zhong L, Yang HY, Wang BL, Yu Y, Liu JJ, Cao ZX, Wang XY, Ji P, Wang ZR, Chen X, Zhang S, Wei YQ, Yang SY*. SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo. Mol Cancer Ther, 2012, 11(4): 952-962. 7. Zhang S, Cao ZX, Tian HW, Shen GB, Ma YP, Xie HZ, Liu YL, Zhao CJ, Deng SY, Yang Y, Zheng RL, Li WW, Zhang N, Liu SY, Wang W, Dai LX, Shi S, Cheng L, Pan YL, Feng S, Zhao X, Deng HX*, Yang SY*, Wei YQ. SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth In Vivo. Clin Cancer Res, 2011, 17(13): 4439-4450. 8. Ren JX, Li LL, Zheng RL, Xie HZ, Cao ZX, Feng S, Pan YL, Chen X, Wei YQ, Yang SY*. Discovery of Novel Pim-1 Kinase Inhibitors by a Hierarchical Multistage Virtual Screening Approach Based on SVM Model, Pharmacophore, and Molecular Docking. J Chem Inf Model, 2011, 51(6): 1364-1375. 9. Huang Q, Li LL, Yang SY*. RASA: A Rapid Retrosynthesis-Based Scoring Method for the Assessment of Synthetic Accessibility of Drug-like Molecules. J Chem Inf Model, 2011, 51(10): 2768-2777. 10. Yang SY*. Pharmacophore Modeling and Applications in Drug Discovery: Challenges and Recent Advances. Drug Discov Today, 2010, 15(11-12): 444-450.